Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com TOPICS:Fashion Posted By: Advance February 26, 2022 Share on FacebookShare on TwitterShare on Pinterest StockNews.com started coverage on Moleculin Biotech in a research note on Sunday. They issued a “sell” rating for the company.
